European Archives - Page 260 of 1369 - European Medical Journal

New Treatment Strategy May Boost Survival in T-Cell Lymphomas

A retrospective analysis of global data has found that a specific treatment sequence, starting with small molecule inhibitors and followed by epigenetic modifiers, may significantly improve survival in patients with relapsed or refractory T-cell lymphomas.

Mirikizumab Shows Promise in Treating Inflammatory Bowel Disease

Read about how mirikizumab shows strong results for IBD, improving remission and response rates.

Lilly partners with Alchemab for ALS candidate

Eli Lilly joins forces with Alchemab in a deal worth $415m, expanding its neuroscience pipeline with a novel candidate.

Triple-Modality Approach Offers Hope for Prostate Cancer

Early results support the theory that combining systemic and localised treatment in oligometastatic prostate cancer can improve tumour control.

Breakthrough for Bronchiectasis: Phase 2 Results of DPP-1 Inhibitor

Discover how HSK31858 could transform bronchiectasis treatment by reducing flare-ups – read more about the latest trial results.

Ultrasound-Guided Tracheostomy Cuts Complications and Boosts First-Puncture Success

Understand how ultrasound-guided PDT improves first-puncture success and reduces bleeding risk compared to landmark guidance.

Maternal Hypertension Linked to Poorer Preterm Infant Neurodevelopment

Find out how maternal hypertension affects preterm infant brain development and why early intervention is crucial – read more.

Calorie Reduction in Gestational Diabetes Shows No Clinical Improvement

Low-energy diets are safe in pregnancy with gestational diabetes but show no clinical benefit in weight or birth weight.

Tackling Heart Failure

Discover cutting-edge advancements in heart failure research, the importance of biomarker-driven care, the challenges of implementing digital health tools globally, and how Norway is reshaping participation in cardiology clinical trials.

How Inflammation Shapes Human Ageing and Health

Researchers developed a new evolutionary framework centred on immune robustness, the ability to fight infection while limiting damage.